Pharmacokinetic Drug Interactions in Veterinary Patients: Mechanisms and Clinical Relevance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Pharmacokinetic drug interactions alter drug concentrations at the site of action by affecting absorption, distribution, metabolism, or excretion, fundamentally differing from pharmacodynamic interactions. The cytochrome P450 enzyme superfamily, particularly CYP inhibition and induction, represents the most common and clinically significant mechanism, impacting drug efficacy and toxicity.
• Altered drug absorption can occur via mechanisms like chelation, changes in gastric pH (e.g., ketoconazole absorption reduced by antacids), or altered gastrointestinal motility (e.g., opioids delaying absorption). These are most relevant for orally administered drugs with narrow therapeutic windows.
• Hepatic metabolism, primarily via cytochrome P450 enzymes, is a major site of interaction. Enzyme inhibition leads to increased parent drug concentrations and potential toxicity, while induction results in decreased concentrations and therapeutic failure, with onset times varying from hours to weeks.
• Species differences in cytochrome P450 enzyme expression and substrate specificity are substantial, making direct extrapolation of interaction data from humans or other animal species unreliable. For example, cats have distinct metabolic pathways that influence drug clearance.
• Liver disease significantly modifies pharmacokinetic interactions, generally reducing the magnitude of enzyme inhibition, particularly reversible inhibition, due to impaired hepatic uptake and reduced enzyme synthesis. This can paradoxically increase toxicity risk if baseline metabolic capacity is already compromised.
• High-clearance drugs, whose elimination is dependent on hepatic blood flow, are vulnerable to interactions that alter cardiac output or portal perfusion. Monitoring cardiovascular parameters and understanding the hepatic extraction ratio of coadministered drugs is crucial for managing these risks.

Pharmacokinetic drug interactions alter the concentration of a drug at its site of action by changing its absorption, distribution, metabolism, or excretion. These interactions differ fundamentally from pharmacodynamic interactions, which modify the drug's effect without changing its concentration. For the practicing veterinarian, recognizing when a pharmacokinetic interaction is likely, predicting its direction and magnitude, and adjusting therapy accordingly can prevent both therapeutic failure and adverse drug events. This article provides a mechanistic framework for understanding these interactions across species, with emphasis on clinically relevant examples and monitoring strategies.

The clinical question this article addresses is practical: when a patient receives two or more drugs concurrently, which combinations warrant dose adjustment, therapeutic drug monitoring, or alternative drug selection? The answer depends on the drug's pharmacokinetic properties, the patient's species and disease status, and the specific enzymes and transporters involved. Species differences in drug metabolism are substantial, and extrapolation from human pharmacology or from one animal species to another carries real risk. This reference serves veterinarians in small animal, equine, and production animal practice who need a systematic approach to anticipating and managing pharmacokinetic interactions.

At a Glance

Mechanisms of Altered Drug Absorption

Interactions at the absorption phase occur when one drug changes the rate or extent of absorption of another. These effects are most clinically relevant for orally administered drugs with narrow therapeutic windows or steep dose-response curves. The mechanisms include chelation and complexation in the gastrointestinal lumen, alteration of gastric pH, changes in gastrointestinal motility, and inhibition or induction of intestinal efflux transporters such as P-glycoprotein.

Gastric pH alteration is a well-recognized mechanism. Drugs that raise gastric pH, such as antacids, H2-receptor antagonists, and proton pump inhibitors, can reduce the dissolution and absorption of weakly basic drugs that require an acidic environment. The azole antifungal ketoconazole provides a classic example: reduced gastric acidity decreases its absorption substantially, and concurrent administration of drugs that raise gastric pH can render ketoconazole therapy ineffective. The interaction between cimetidine and ketoconazole, where cimetidine reduces ketoconazole plasma concentrations through impaired absorption, illustrates this principle in clinical terms pharmacokinetic interactions of cimetidine.

Motility-altering drugs also affect absorption. Drugs that slow gastric emptying, such as opioids or anticholinergics, delay the delivery of orally administered drugs to the small intestine, where most absorption occurs. This delay does not necessarily reduce total absorption, but it can delay the time to peak concentration and, for drugs used to treat acute conditions, delay the onset of effect. Conversely, prokinetic agents that accelerate gastric emptying can hasten absorption and increase peak concentrations.

Distribution Interactions

Distribution interactions occur when one drug displaces another from plasma protein binding sites or alters tissue binding. Albumin is the primary binding protein for acidic drugs, while alpha-1-acid glycoprotein binds basic drugs. Displacement interactions are most clinically significant for drugs that are highly protein bound, defined as greater than 90 percent bound, and that have a small volume of distribution.

The clinical importance of protein binding displacement is frequently overstated. For most drugs, an increase in the free fraction is transient because the liver and kidney clear free drug more rapidly, and a new steady state is reached with total drug concentration reduced but free drug concentration similar to baseline. Clinically significant interactions require the displaced drug to have a narrow therapeutic index and saturable clearance. The practical implication is that measuring total drug concentration after a suspected displacement interaction can be misleading, since total concentration falls while free concentration remains therapeutic.

Hepatic Metabolism and Cytochrome P450 Enzymes

The cytochrome P450 enzyme superfamily is the dominant site of pharmacokinetic drug interactions in veterinary patients. These membrane-bound enzymes, located primarily in the liver and intestinal epithelium, catalyze the oxidative metabolism of a vast range of drugs, environmental chemicals, and endogenous substrates. Inhibition and induction of these enzymes are the most frequent and dangerous drug-drug interactions in clinical medicine pharmacokinetic drug interactions in liver disease.

Enzyme inhibition is generally rapid in onset, occurring within hours to days of adding the inhibitor, because it depends on the inhibitor reaching sufficient concentration at the enzyme site instead of on new protein synthesis. Inhibition can be competitive, where the inhibitor and substrate compete for the same active site, or mechanism-based, where the inhibitor is metabolized to a reactive intermediate that irreversibly inactivates the enzyme. Mechanism-based inhibition produces more prolonged effects because recovery requires synthesis of new enzyme.

Enzyme induction is slower in onset, typically requiring days to weeks, because it involves increased gene transcription and enzyme protein synthesis. Inducers such as phenobarbital increase both the rate of metabolism of substrates and, often, hepatic blood flow. The clinical consequence is reduced plasma concentrations of concurrently administered drugs that are substrates of the induced enzyme, potentially leading to therapeutic failure.

The magnitude of an enzyme-mediated interaction depends on the fraction of the drug metabolized by the affected pathway. A drug that is exclusively metabolized by CYP3A will show a large interaction when CYP3A is inhibited, whereas a drug with multiple metabolic pathways will show a smaller change. This principle explains why some drug combinations require substantial dose adjustment while others can be managed with increased monitoring.

Species Differences in Cytochrome P450 Expression

Domestic species differ substantially in the expression and substrate specificity of individual cytochrome P450 enzymes. Cats are notably deficient in certain glucuronidation pathways, which affects their ability to metabolize drugs such as acetaminophen. Dogs, cats, horses, and ruminants each have distinct patterns of CYP enzyme expression, and the specific enzymes responsible for metabolizing a given drug in one species may differ from those in another. Extrapolating interaction data from humans or from one veterinary species to another is therefore unreliable.

Ketamine illustrates the importance of understanding species-specific metabolic pathways. Ketamine undergoes oxidative metabolism primarily to norketamine via CYP3A and CYP2B6 enzymes ketamine clinical pharmacokinetics review. Because of extensive first-pass metabolism, oral bioavailability is poor, and ketamine is vulnerable to pharmacokinetic drug interactions at the level of hepatic and intestinal metabolism. Concurrent administration of CYP3A inhibitors can increase ketamine concentrations, while inducers can reduce its efficacy.

Hepatic Blood Flow and High-Clearance Drugs

Drugs with high hepatic extraction ratios, where the liver removes a large fraction of the drug presented to it in a single pass, have clearance that depends on hepatic blood flow instead of on enzyme activity. For these drugs, any concurrent medication that alters hepatic blood flow can change their clearance. Examples include drugs that reduce cardiac output, such as beta-blockers, or drugs that cause hepatic vasoconstriction.

Thrombolytic agents such as alteplase are high-clearance compounds whose clearance depends on hepatic blood flow drug interactions with thrombolytic agents. Any pharmacological agent that alters hepatic blood flow and is given concurrently can change plasma concentrations of these agents, with potential consequences for both efficacy and bleeding risk. This principle extends to veterinary patients receiving drugs with high hepatic extraction, where concurrent medications affecting cardiovascular function warrant careful consideration.

The Effect of Liver Disease on Interactions

Liver disease modifies the magnitude of pharmacokinetic interactions, and this effect is clinically important in veterinary patients with hepatic dysfunction. Clinical studies show that liver disease reduces the magnitude of interactions due to enzyme inhibition, and this reduction is proportional to the degree of liver function impairment pharmacokinetic drug interactions in liver disease. The effect differs by the nature of the inhibition. Reversible inhibition is more drastically reduced and virtually vanishes in patients with advanced hepatocellular insufficiency, because decreased hepatic uptake of the inhibitory drug and reduced enzyme expression both contribute. Irreversible, mechanism-based inhibition is only partially reduced, since it depends less on the amount of inhibitor reaching the liver.

For the clinician, this means that a drug interaction predicted from healthy-animal data may be smaller or absent in a patient with significant liver disease. Conversely, the patient with liver disease already has reduced metabolic capacity, and the addition of even a weak inhibitor may push drug concentrations into the toxic range. The net effect is difficult to predict without therapeutic drug monitoring, and clinical judgment guided by careful observation of response and adverse effects is essential.

Practical Assessment of Pharmacokinetic Interactions

The clinical evaluation of a suspected pharmacokinetic interaction begins with a structured history. Obtain a complete drug list, including topical preparations, compounded products, supplements, and any medications administered by the owner without veterinary oversight. Record the dose, route, frequency, and duration for each agent. Establish the temporal relationship between drug administration and the onset of clinical signs, because interactions that appear within hours of adding a new drug differ mechanistically from those that emerge after days of coadministration.

The physical examination should target organ systems most likely to reveal altered drug effect. Assess for signs of drug toxicity, such as sedation, gastrointestinal upset, arrhythmia, or bleeding, and for signs of therapeutic failure, such as persistent pain, fever, or seizure activity. Baseline laboratory data, including serum biochemistry, complete blood count, and urinalysis, help identify hepatic or renal dysfunction that may amplify an interaction. Liver disease reduces the magnitude of enzyme inhibition interactions in proportion to the degree of functional impairment, so a patient with hepatocellular insufficiency may paradoxically show a smaller change in drug exposure when an inhibitor is added, while remaining at higher baseline risk of toxicity from reduced clearance.

Decision Framework for Suspected Interactions

When an interaction is suspected, classify it by the most probable pharmacokinetic phase. The table below provides a working framework for this classification and the corresponding monitoring approach.

The threshold values in this table are clinical decision points, not absolute numbers. For drugs with established therapeutic ranges, such as phenobarbital or digoxin, serum concentration monitoring provides the most objective guide. For drugs without validated assays in veterinary species, rely on serial clinical assessment and targeted laboratory parameters.

Monitoring Parameters and Their Interpretation

Monitoring serves two distinct purposes: detecting toxicity and confirming efficacy. The choice of parameters depends on the drug pair and the patient's organ function.

For CYP-mediated interactions, serial measurement of the affected drug's serum concentration is the gold standard when an assay is available. Ketamine undergoes extensive first-pass metabolism and is vulnerable to pharmacokinetic drug interactions, so concurrent administration of CYP3A inhibitors such as ketoconazole or itraconazole may increase ketamine exposure after oral or transmucosal dosing. Monitor for prolonged sedation, respiratory depression, or emergence phenomena in patients receiving this combination.

Hepatic enzyme activity can be assessed indirectly through probe substrates. Caffeine clearance serves as a validated marker for CYP1A2 activity, and systemic methoxsalen therapy markedly inhibits CYP1A2, reducing caffeine clearance to below reference ranges. In veterinary patients receiving methoxsalen for dermatologic conditions, concurrent drugs metabolized by CYP1A2, such as theophylline, may require dose reduction. Bath PUVA does not produce this effect, so the route of methoxsalen administration determines the interaction risk.

Cardiovascular monitoring is essential for drugs that alter hepatic blood flow. High-clearance drugs such as lidocaine, propranolol, and certain thrombolytic agents have clearance that depends on liver perfusion. Any pharmacological agent that alters hepatic blood flow can change the plasma concentrations of high-clearance thrombolytic compounds. Drugs that reduce cardiac output, such as beta-blockers or potent vasodilators, may decrease hepatic blood flow and increase the plasma concentration of coadministered high-clearance drugs. Monitor heart rate, blood pressure, and perfusion parameters, and reduce doses of high-clearance drugs when hemodynamic compromise is present.

Species-Specific Considerations

Species differences in drug metabolism are substantial and directly affect interaction risk. Cats are deficient in several glucuronosyltransferase isoforms, making them more susceptible to toxicity from drugs that rely on this pathway. Dogs express CYP2D15 instead of the human CYP2D6, and breed-specific polymorphisms in drug transporters and metabolic enzymes produce clinically meaningful variability. Tamoxifen and ondansetron are metabolized via the CYP2D subfamily and CYP3A in rats, as in humans, and ondansetron inhibits tamoxifen metabolism in this model, illustrating how cross-species extrapolation of interaction mechanisms requires caution.

Ruminants present additional complexity because ruminal metabolism can alter drug bioavailability before systemic absorption. Oral drugs in cattle and sheep may be degraded by ruminal microflora, and coadministered agents that alter ruminal pH or motility can change the extent of this degradation. The practical consequence is that oral drug interactions in ruminants are less predictable than in monogastric species, and parenteral administration may be preferred when interaction risk is high.

Documentation and Communication

Document the suspected interaction, the evidence supporting it, and the management plan in the medical record. Include the temporal sequence of drug administration, the specific clinical signs observed, and the monitoring parameters selected. If a dose adjustment is made, record the rationale and the target therapeutic endpoint. Communicate the interaction risk to the owner in terms of observable signs that warrant re-evaluation, such as increased sedation, vomiting, or lack of expected therapeutic response.

For production animals, consider withdrawal period implications when drug interactions alter elimination. Regulatory oversight of approved animal drugs, labeling, and extralabel use is provided by the FDA Center for Veterinary Medicine, and practitioners must consult current label and formulary references when an interaction may affect tissue residue profiles. The absence of species-specific interaction data does not mean the interaction does not occur, it means the clinician must extrapolate from mechanistic principles and monitor accordingly.

When Evidence Is Limited

Many pharmacokinetic interactions in veterinary patients are documented only through case reports, extrapolation from human medicine, or in vitro studies. Cimetidine interactions have been extensively studied, but very few investigations have measured pharmacodynamic responses or clinical endpoints, and the same limitation applies to most veterinary interaction data. Acknowledge this uncertainty in the medical record and in client communication. When the evidence base is thin, choose the monitoring strategy that detects the most likely adverse outcome, and revisit the plan at defined intervals.

The absence of a documented interaction for a specific drug pair does not establish safety. If the mechanism is plausible and the consequences of toxicity are severe, dose reduction or increased monitoring frequency is justified even without published veterinary data. Conversely, avoid unnecessary dose changes when the interaction is theoretical and the therapeutic index of the affected drug is wide. The decision rests on the balance between the probability of harm and the cost of altered therapy.

Recognized Complications and Early Detection

Pharmacokinetic interactions fail in predictable patterns. The most common failure is unrecognised enzyme inhibition presenting as exaggerated drug effect. A patient receiving a CYP inhibitor alongside a narrow-therapeutic-index drug develops toxicity days after the second drug is added, not immediately. Early detection depends on scheduled re-evaluation after any new drug is introduced, with particular attention to drugs whose adverse effects mimic disease progression. For example, a patient on methoxsalen-based systemic PUVA therapy shows reduced caffeine clearance within one day of treatment, and this inhibition persists for at least one week, so any concurrently administered CYP1A2 substrate should be reassessed at the first follow-up visit instead of at the next scheduled recheck.

A second failure mode is the opposite: enzyme induction leading to subtherapeutic concentrations. This presents as loss of efficacy, often attributed incorrectly to dose insufficiency or disease progression. The discriminating question is temporal. If the patient was stable on a drug for months and then loses response within one to two weeks of starting a new medication, an induction interaction is more likely than spontaneous disease worsening.

A third failure mode involves high-clearance drugs whose disposition depends on hepatic blood flow. Any concurrent drug that alters cardiac output or hepatic perfusion changes plasma concentrations of these agents, and the effect can be rapid and clinically significant. Detection requires knowing which drugs in the formulary are high-clearance and which concurrent medications affect perfusion, instead of relying on adverse event monitoring alone.

Common Errors and Corrective Actions

Less experienced clinicians often assume that interactions require both drugs to be metabolised by the same enzyme. This is incorrect. One drug may inhibit an enzyme while the other is a substrate, and the inhibitor need not be metabolised by that enzyme at all. Cimetidine illustrates this pattern: it inhibits multiple CYP enzymes while being metabolised by only some of them, and it also reduces absorption of certain drugs such as ketoconazole by raising gastric pH. The corrective action is to check the metabolic profile of each drug independently and then compare substrate and inhibitor relationships.

A second common error is extrapolating interaction magnitude from one species to another without adjustment. Enzyme expression differs across species, and so does the clinical impact of a given inhibitor. The same interaction that is clinically important in one species may be negligible in another. The corrective action is to consult species-specific pharmacology references and to treat cross-species extrapolation as hypothesis, not fact.

A third error is ignoring disease state as a modifier of interaction magnitude. Liver disease reduces the magnitude of enzyme inhibition interactions, and the reduction is proportional to the degree of hepatic impairment. Reversible inhibition virtually disappears in advanced hepatocellular insufficiency, while irreversible inhibition is only partially reduced. A clinician who expects the same interaction magnitude in a patient with cirrhosis as in a healthy patient will either overtreat or undertreat.

Limitations of Current Evidence

The evidence base for pharmacokinetic interactions in veterinary patients is thinner than in human medicine. Most interaction data derive from human studies, rodent models, or in vitro systems, and extrapolation to clinical veterinary patients carries real uncertainty. For example, ondansetron increases tamoxifen exposure in rats through inhibition of CYP2D and CYP3A-mediated metabolism, but whether this interaction reaches clinical significance in dogs or cats with mammary tumors is not established. Similarly, ketamine is known to undergo CYP3A and CYP2B6 metabolism and is vulnerable to interactions because of extensive first-pass metabolism, yet the clinical interaction profile in veterinary species is inferred largely from human data.

Expert opinion still differs on how aggressively to manage potential interactions in the absence of species-specific data. Some clinicians adjust doses pre-emptively when an interaction is mechanistically plausible. Others prefer to monitor and adjust only when an effect is observed. Both positions are defensible, and the choice depends on the therapeutic index of the drug, the severity of the disease being treated, and the feasibility of monitoring.

Referral, Consultation, and Reporting

Referral or specialist consultation is warranted when a suspected interaction involves a drug with a narrow therapeutic index, when the patient has concurrent hepatic or renal disease that complicates dose adjustment, or when the interaction cannot be managed by dose modification alone. Clinical pharmacology services at veterinary teaching hospitals can provide quantitative guidance, including therapeutic drug monitoring where assays exist.

Laboratory involvement is appropriate when measuring drug concentrations would clarify the interaction, when hepatic or renal function needs formal assessment to predict interaction magnitude, or when a suspected adverse drug reaction requires documentation. For production animals, withdrawal period implications of an interaction must be considered, and current label and regulatory references should be consulted before any extralabel adjustment is made.

Regulatory reporting is required when an adverse event is suspected to be drug-related, particularly for approved animal drugs. Practitioners should report through the relevant national pharmacovigilance system, and the FDA Center for Veterinary Medicine provides channels for adverse event reporting in the United States. Antimicrobial interactions that compromise treatment efficacy also carry stewardship implications, and professional guidance on judicious antimicrobial use should inform clinical decisions. International movement of treated animals may be affected by residue concerns, and the World Organization for Animal Health terrestrial standards provide relevant context for trade-related decisions.

Frequently Asked Questions

How Should I Prioritize Suspected Pharmacokinetic Interactions When Cost Limits Diagnostic Testing?

Start with the clinical risk assessment. If the patient is stable and the interaction is theoretical, adjust monitoring frequency instead of pursuing costly assays. If the drug has a narrow therapeutic index, such as digoxin or ciclosporin, assume the interaction is present and adjust therapy empirically. Serum drug concentration testing is most valuable when a validated assay exists for the species and the result will change management. When assays are unavailable, use clinical endpoints such as heart rate, blood pressure, sedation score, or pain response as surrogate markers. Document your reasoning clearly. The FDA Center for Veterinary Medicine maintains product-specific information that may clarify whether a known interaction is listed on the label.

What Should I Do When I Cannot Measure Hepatic Enzyme Activity Directly?

Use a pragmatic functional assessment. Serial measurement of a drug with well-characterized clearance, such as caffeine for CYP1A2 activity, can serve as a bedside probe in species where the assay is available. In most practices, however, you will rely on indirect markers: albumin, bilirubin, bile acids, and clotting times give a static picture, while serial lactate and blood glucose trends reflect perfusion and metabolic stability. For high-clearance drugs whose elimination depends on hepatic blood flow, monitor for exaggerated effect after dosing and extend the interval between doses instead of reducing the dose, since the latter may produce subtherapeutic peaks. The MSD Veterinary Manual offers species-specific guidance on interpreting liver function tests in context.

How Do Pharmacokinetic Interactions Differ Between Dogs and Cats in Practical Terms?

Cats are deficient in several glucuronidation pathways, so drugs that rely on this route for clearance accumulate more readily when a second drug inhibits metabolism. Dogs have greater capacity for oxidative metabolism via cytochrome P450 enzymes, but they also show wider interindividual variability in enzyme expression, making interaction magnitude less predictable. For drugs such as ketamine, which is metabolised by CYP3A and CYP2B6, concurrent administration of an inhibitor can prolong recovery in both species, but the clinical effect is more pronounced in cats because of their slower overall oxidative capacity. Always consult a current formulary for species-specific dosing adjustments, and recognize that extrapolation from human interaction data is unreliable when enzyme orthologues differ in substrate specificity.

What Records Should I Keep When Managing a Potential Drug Interaction?

Record the suspected interacting drugs, the mechanism you identified, the temporal relationship between co-administration and the observed effect, and the monitoring parameters you selected. Include the rationale for any dose adjustment and the clinical response to that adjustment. If you discontinued one drug, note the washout period you allowed before resuming the other. This documentation supports future prescribing decisions for the same patient and contributes to practice-level pharmacovigilance. The AVMA practice resources provide templates for adverse event documentation, and the FDA Center for Veterinary Medicine accepts reports of suspected adverse drug events, including interactions, from licensed veterinarians.

How Should I Explain a Drug Interaction to a Client Without Causing Alarm?

Frame the interaction as a planned part of therapy instead of an error. State that the combination is being used deliberately, that the dose or dosing interval has been adjusted accordingly, and that you will monitor specific signs at home. Give the client two or three concrete observations to report, such as vomiting, lethargy, or changes in urination, and tell them whom to contact. Avoid listing every theoretical adverse effect. Explain that the body processes medications through pathways that can be shared, and that your adjustment accounts for that sharing. Reassure the client that monitoring is routine and that you will reassess at the next visit. This approach preserves compliance while maintaining realistic expectations.

When Should I Suspect an Interaction instead of Disease Progression?

Suspect an interaction when the timing fits: onset of the unexpected effect follows addition of a new drug or a dose change within one to two elimination half-lives of the affected drug. Look for a dose-response relationship, where the effect intensifies as the interacting drug accumulates. If the patient's underlying disease is stable by objective measures, such as imaging, laboratory values, or pain scores, an interaction becomes more likely. Withdrawal of the suspected interacting drug should produce gradual resolution over several half-lives. If the effect does not abate, reconsider the diagnosis. For drugs with high first-pass metabolism, such as ketamine, interactions at the level of absorption or presystemic clearance can produce effects that appear rapidly after oral dosing, so ask specifically about timing relative to medication administration.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.. 2016.
• Pharmacokinetic interactions of cimetidine 1987.. 1987.
• Pharmacokinetic drug interactions in liver disease: An update.. 2016.
• Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients.. 2001.
• Pharmacokinetic drug interactions between ondansetron and tamoxifen in female Sprague-Dawley rats with DMBA-induced mammary tumor.. 2013.
• Drug interactions with thrombolytic agents. Current perspectives.. 1995.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Drug Interactions with NSAIDs in Veterinary Patients: Mechanisms and Clinical Management
• Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations
• Drug Interactions with Fluoroquinolones in Veterinary Patients: Mechanisms and Management
• Drug Interactions with Opioid Analgesics in Veterinary Patients: Clinical Implications
• Drug Interactions with Antihypertensive Medications in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.